Literature DB >> 19255113

Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel.

Zhong Wang1, Steven Tobler, Jean Roayaei, Angelia Eick.   

Abstract

CONTEXT: Since 2004, increasing numbers of military personnel have been immunized with the intranasal live attenuated influenza vaccine (LAIV) while most others received the trivalent inactivated vaccine (TIV). However, data about live virus vaccine effectiveness among healthy adults are limited.
OBJECTIVE: To monitor the effectiveness of vaccines to better inform military vaccination policy. DESIGN, SETTING, AND PARTICIPANTS: Surveillance of population-based, propensity-matched, and/or vaccine-naive cohorts of more than a million active-duty, nonrecruit military service members aged 17 to 49 years stationed in the United States during the 2004-2005, 2005-2006, or 2006-2007 influenza season. MAIN OUTCOME MEASURES: Incidence of health care encounters resulting in a primary diagnostic code consistent with pneumonia or influenza. Incident hospitalizations was a secondary outcome.
RESULTS: In all 3 seasons, immunization with TIV was associated with lower incidence rates of health care encounters for pneumonia and influenza when compared with no immunization: 8.6 vs 19.4 for 2004-2005, 7.8 vs 10.9 for 2005-2006, and 8.0 vs. 11.7 per 1000 person-years for 2006-2007 (all P < .001). Similar estimates were obtained from propensity-matched and/or vaccine-naive cohorts. Consistently lower vaccine effect following LAIV immunization was only seen during the 2006-2007 influenza season in the total (10.7; 95% confidence interval [CI], 2.72 to 18.1; P = .03) and propensity-matched cohorts (11.8; 95% CI, 0.85 to 21.5; P = .04), and was less than effect from TIV (TIV vs LAIV, 19.8; 95% CI, 13.6 to 25.5; P < .001). Among vaccine-naive service members, however, estimates for LAIV effect were more robust for both the 2005-2006 and 2006-2007 seasons (P = .01) and were comparable with TIV (eg, LAIV, 30.2; 95% CI, 11.2 to 45.2; vs TIV, 35.3; 95% CI, 25.9 to 43.6; in 2005-2006).
CONCLUSIONS: Vaccination with TIV was associated with fewer medical encounters related to pneumonia and influenza compared with LAIV or no immunization. In this annually immunized population, this effect was less apparent in those vaccinated with LAIV.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19255113     DOI: 10.1001/jama.2009.265

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  33 in total

Review 1.  Influenza vaccines: from surveillance through production to protection.

Authors:  Pritish K Tosh; Robert M Jacobson; Gregory A Poland
Journal:  Mayo Clin Proc       Date:  2010-01-29       Impact factor: 7.616

2.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

3.  Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial.

Authors:  Rong Deng; Ai Ping Lee; Mauricio Maia; Jeremy J Lim; Tracy Burgess; Priscilla Horn; Michael A Derby; Elizabeth Newton; Jorge A Tavel; William D Hanley
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

Review 4.  Inactivated split-virion seasonal influenza vaccine (Fluarix): a review of its use in the prevention of seasonal influenza in adults and the elderly.

Authors:  Monique P Curran; Isabel Leroux-Roels
Journal:  Drugs       Date:  2010-08-20       Impact factor: 9.546

5.  Recommendations on the use of live, attenuated influenza vaccine (FluMist®): Supplemental Statement on Seasonal Influenza Vaccine for 2011-2012 An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2011-11-30

6.  Comparisons of the Humoral and Cellular Immune Responses Induced by Live Attenuated Influenza Vaccine and Inactivated Influenza Vaccine in Adults.

Authors:  Daniel F Hoft; Kathleen R Lottenbach; Azra Blazevic; Aldin Turan; Tamara P Blevins; Thomas P Pacatte; Yinyi Yu; Michelle C Mitchell; Stella G Hoft; Robert B Belshe
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

7.  M2SR, a novel live single replication influenza virus vaccine, provides effective heterosubtypic protection in mice.

Authors:  Sally Sarawar; Yasuko Hatta; Shinji Watanabe; Peter Dias; Gabriele Neumann; Yoshihiro Kawaoka; Pamuk Bilsel
Journal:  Vaccine       Date:  2016-09-03       Impact factor: 3.641

8.  Evaluation of the attenuation, immunogenicity, and efficacy of a live virus vaccine generated by codon-pair bias de-optimization of the 2009 pandemic H1N1 influenza virus, in ferrets.

Authors:  Andrew J Broadbent; Celia P Santos; Amanda Anafu; Eckard Wimmer; Steffen Mueller; Kanta Subbarao
Journal:  Vaccine       Date:  2015-12-02       Impact factor: 3.641

9.  Seasonal influenza vaccine and protection against pandemic (H1N1) 2009-associated illness among US military personnel.

Authors:  Matthew C Johns; Angelia A Eick; David L Blazes; Seung-eun Lee; Christopher L Perdue; Robert Lipnick; Kelly G Vest; Kevin L Russell; Robert F DeFraites; Jose L Sanchez
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

10.  Live attenuated influenza virus vaccines by computer-aided rational design.

Authors:  Steffen Mueller; J Robert Coleman; Dimitris Papamichail; Charles B Ward; Anjaruwee Nimnual; Bruce Futcher; Steven Skiena; Eckard Wimmer
Journal:  Nat Biotechnol       Date:  2010-06-13       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.